Abstract: Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

Abstract: Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

Abstract: Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

Abstract: A process for the production of furan derivatives from D-glucose, wherein A) D-glucose is converted into D-fructose in an enzymatic process, wherein redox cofactors are used and regenerated, whereby, as a result of at least two further enzymatically catalyzed redox reactions proceeding in the same reaction batch, one of the two redox cofactors accumulates in its reduced form and, respectively, the other one in its oxidized form, whereby D-glucose is converted into D-fructose, involving two or more oxidoreductases, and B) D-fructose is converted into furan derivatives, and the use of furan derivatives produced in this manner.

Abstract: A compound of formula (II), and a method of preparation thereof, for use as a smooth muscle cell (SMC) proliferation-inhibiting drug: wherein: R1 to R6 are —H, —F, —CH3, —CF3, —CF2CH3, —OCH3, —COCH3, —C4H9, —COOC2H5, or —C6H5, or two vicinal residues from R1 to R6 form a saturated or unsaturated carbocyclic ring together with the two carbon atoms to which they are attached; R7 is OH, allyloxy, propargyl-oxy, 2,2-dimethylpropanoyloxy (pivaloyloxy), butanoyloxy, 3-methylbutanoyloxy, 2-buten-oyloxy, 2-methyl-2-butenoyloxy, 3-methyl-2-butenoyloxy, isopentanoyloxy, 2-ethylbutanoyl-oxy, 3,3-dimethylbutanoyloxy, cyclopropylcarbonyloxy, cyclobutylcarbonyloxy, cyclo-pentylcarbonyloxy, cyclopentenylcarbonyloxy, cyclohexylcarbonyloxy, cyclo-hexenylcarbonyloxy, adamantylethanoyloxy, 3-phenylpropenoyloxy (cinnamyloyloxy), 2-methylbenzoyloxy, or naphthoyloxy; wherein, in ring A and/or B, one or more carbon ring atoms are optionally replaced by heteroatoms; wherein the compounds of formula (II) are obtained by combining

Abstract: Process for the selective production of oxidized furan derivatives starting from 5-hydroxymethyl-2-furfural in the presence of a solvent, an oxidation agent, a catalyst, and optionally a base, which process is characterized in that the oxidation process is carried out continuously in flow, and there are provided means for varying reaction parameters.

Abstract: A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently —NR4—or —O—, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C1-6-alkylamino, or di-C1-6-alkylamino, the C1-6-alkyl or -alkoxy residue being optionally substituted with one or more R5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R2 is hydrogen, aryl, heteroaryl, or C1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R1 substituents, and where the C1-6-alkyl is optionally further substituted with one or more R5 substituents; and R3 is selected from hydrogen, halo, NR4R7, OR7, SR7, and R7, where the same options apply for R7 as for R2; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.

Abstract: A process for the production of furan derivatives from carbohydrates in the presence of an acidic catalyst, characterized in that N-methylpyrrolidone is used as a solvent and that the acidic catalyst is homogeneous.

Abstract: A process for the production of furan derivatives from carbohydrates in the presence of an acidic catalyst, characterized in that N-methylpyrrolidone is used as a solvent and that the acidic catalyst is homogeneous.

Abstract: Provided are compounds of formula (I) and/or salts thereof, of the class of substituted pyridines and pyrimidines, useful for inducing cardiomyogenesis, a process for producing cardiomyocyte-like cells from mammalian cells by culturing mammalian cells in the presence of the compound of formula (I), the pharmaceutical use of compounds of formula (I) for producing cardiomyocyte-like cells from omnipotent, pluripotent, or lineage committed mammalian cells, and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.

Abstract: A process for the production of furan derivatives from D-glucose, wherein A) D-glucose is converted into D-fructose in an enzymatic process, wherein redox cofactors are used and regenerated, whereby, as a result of at least two further enzymatically catalyzed redox reactions proceeding in the same reaction batch, one of the two redox cofactors accumulates in its reduced form and, respectively, the other one in its oxidized form, whereby D-glucose is converted into D-fructose, involving two or more oxidoreductases, and B) D-fructose is converted into furan derivatives, and the use of furan derivatives produced in this manner.

Abstract: A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently —NR4— or —O—, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C1-6-alkylamino, or di-C1-6-alkylamino, the C1-6-alkyl or -alkoxy residue being optionally substituted with one or more R5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R2 is hydrogen, aryl, heteroaryl, or C1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R1 substituents, and where the C1-6-alkyl is optionally further substituted with one or more R5 substituents; and R3 is selected from hydrogen, halo, NR4R7, OR7, SR7, and R7, where the same options apply for R7 as for R2; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.

Abstract: A device is provided for cooling or heating vessels and containers for carrying out chemical or physical reactions. The device includes the following components in a vertical direction from top to bottom: a heat-conductive cooling or heating plate; at least one Peltier element equipped with electrical connections; optionally at least one heat-conductive separator plate between two Peltier elements respectively; a heat-conductive thermoblock, through which one or more fluid channels pass, for dissipation and supply of heat from and to the at least one Peltier element; and an external control unit for the at least one Peltier element. The components rest on top of one another and are therefore in direct planar contact with one another.

Abstract: Provided is a compound of formula (I), and/or salt thereof, wherein the radicals have various meanings, a process for producing cardiomyocyte-like cells from mammalian cells by culturing mammalian cells in the presence of the compound of formula (I), the pharmaceutical use of compounds of formula (I) for producing cardiomyocyte-like cells from omnipotent, pluripotent, or lineage committed mammalian cells, and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.